Liposomal bupivacaine did not reduce inpatient opioid prescription or opioid-related complications after total knee arthroplasty, according to a study in Anesthesiology.
The study assessed data on 88,830 total knee arthroplasties performed with a peripheral nerve block between 2013 to 2016; liposomal bupivacaine was used as part of a multimodal approach to manage postsurgical pain in 18,817 patients.
Liposomal bupivacaine use was not associated with a clinically meaningful reduction in inpatient opioid prescription and length of stay. It had no effect on the cost of hospitalization.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. Todd J. Albert of Hospital for Special Surgery
Drs. Armin Tehrany, Derek Kelly & more: 6 orthopedic surgeons making headlines
Dr. Paul Dale performs 5,000th Joint Replacement Center surgery: 4 things to know